KMPH The Next GME Sleeping Giant?I brought up this idea on WSBN discord about a week ago and I think it's starting to line up.
Just as GME was a heavily shorted stock so has been KMPH with a 71% short interest as of yesterday.
The company has a major catalyst with an FDA approved ADHD drug that is better than anything else out there on the market.
Having ADHD I have been very interested in this company.
When I spoke about this on WSBN on discord, before I was suddenly banned, there was a volume spike two minutes after. Since then some major twitter hedge fund guys have taken my idea and I wanted to get it out here.
With most of the shorting around 10.50 a share and such a big amount of the float available to short already shorted, if the stock stays above 11.00 this week you could see shorts starting to cover.
Also compared to GME, KMPH has a significantly smaller float so it could really rip in the pre or post markets without a circuit breaker kicking in it could see 60.00 a share in a GME squeeze like scenario. Also at this price KMPH could be a take out target as the last ADHD drug company that got FDA approval was swallowed up by Johnson&Johnson.
The company missed earnings, but they have the new ADHD drug, have zero debt, and have analysts rerating them to the upside.
Full disclosure I'm Long 1500 shares and I intend to ride this company to 100.00 per share or more.
KMPH
KMPH $50 Million Share Repurchase ProgramWhen most of the companies are diluting their shares and insiders are selling, KemPharm, Inc. (KMPH) does the opposite.
Insiders are buying and the Board of Directors authorizes a program to repurchase up to $50 million of the Company’s outstanding stock valid through December 31, 2023. It is equivalent to 18% of KemPharm’s current market capitalization.
Because of the short term puts i have 2 approaches for KMPH:
dump to 7.17 and then go to 11.45
or
bounce from the strong support which it has right now and go to $14.50
Looking forward to read your opinion about it.
KMPH Kempharm targets after the volume spikeTarget 1: $29
Target 2: $45
Target 3: $80
If you are interested to test some amazing BUY and SELL INDICATORS which give the signal at the beginning of the candle, not at the end of it, just leave me a message.
Kempharm $KMPH potentially due to slip much further- SHORT$KMPH has very weak support and could retrace much lower regions in near completion of a head and shoulders formation. All signs are grossly bearish, including many large-scale sell orders having been placed in the last five days. The bigger investors have pulled the rug-- Target new entries much lower on this position if possible.
Best,
BDR
#KMPH is going to blow the market up? KemPharm, Inc., a specialized pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its candidate product includes KP415 and KP484 for the treatment of attention deficit disorder. (ADHD) For reference: ADHD has a huge market and no cures have been invented in over 10 years. If the KP415 is FDA approved (March 2), it will be the first major shift since Vyvanse hit the market in 2007. The ADHD market is priced
at $ 24 billion in 2024. An interesting fact is that Vyvanse was invented by Travis Mikal and his team of scientists while they were working on New River and later acquired this company for 2.6 billion US dollars. This team is currently working on KP415 at KemPharm. With the approval of the drug, the company has great prospects, since this drug is superior to its counterpart, as the developers themselves say. We go in a small position
Short term - 14$
Long term - 20/40$
KMPH goes to $15-20 off PDUFA hypeI am only playing the run up, but it has been said it is very likely FDA approves their drug.
My run up target before March 2 is $15-20.
